Clinical Observation on Tiotropium Bromide Combined with Salmeterol Xinafoate and Fluticasone Propio-nate in the Treatment of Medium and Severe COPD
10.6039/j.issn.1001-0408.2016.35.24
- VernacularTitle:噻托溴铵联合沙美特罗替卡松治疗中重度COPD的临床观察
- Author:
Hongyan LU
;
Chen FU
- Keywords:
COPD;
Salmeterol xinafoate and fluticasone propionate;
Tiotropium bromide;
Lung function;
Blood gas index;
Inflammatory factor
- From:
China Pharmacy
2016;27(35):4971-4973
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical effect of tiotropium bromide combined with salmeterol xinafoate and fluticasone propionate in the treatment of medium and severe COPD. METHODS:119 patients with medium and severe COPD were divided into control group(54 cases)and observation group(65 cases)according to admission order. Control group was treated with Salmeterol xi-nafoate and fluticasone propionate powder for inhalation 50 μg,bid;observation group was additionally given Tiotropium bromide powder for inhalation 18μg,qn. Both groups received 1 month of treatment. Lung function indexes as FEV1,FVC and IC,blood gas indexes as SaO2,PaCO2 and PaO2 and inflammatory factors as IL-8 and TNF-α,COPD assessment test(CAT)score were observed in 2 groups,and the occurrence of ADR was also observed. RESULTS:Before treatment,there was no statistical significance in above indexes between 2 groups(P>0.05). After treatment,FEV1,EVC,IC of observation group were increased significantly,SaO2 and PaO2 of observation group were increased significantly,while PaCO2,IL-8 and TNF-αlevels was decreased significantly;those index-es of observation group were significantly better than those of control group,with statistical significance(P<0.05). CAT score of 2 groups were decreased significantly compared to before treatment,and the observation group was significantly lower than control group,with statistical significance(P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:Tiotropium bromide com-bined with salmeterol xinafoate and fluticasone propionate shows good clinical efficacy and safety in the treatment of medium and se-vere COPD.
